These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

65 related items for PubMed ID: 1350753

  • 1. Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation.
    Lothstein L, Sweatman TW, Dockter ME, Israel M.
    Cancer Res; 1992 Jun 15; 52(12):3409-17. PubMed ID: 1350753
    [Abstract] [Full Text] [Related]

  • 2. N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance.
    Lothstein L, Hosey LM, Sweatman TW, Koseki Y, Dockter M, Priebe W.
    Oncol Res; 1993 Jun 15; 5(6-7):229-34. PubMed ID: 7907237
    [Abstract] [Full Text] [Related]

  • 3. N-benzyladriamycin-14-valerate and drug resistance: correlation of anthracycline structural modification with intracellular accumulation and distribution in multidrug resistant cells.
    Lothstein L, Wright HM, Sweatman TW, Israel M.
    Oncol Res; 1992 Jun 15; 4(8-9):341-7. PubMed ID: 1362503
    [Abstract] [Full Text] [Related]

  • 4. P-glycoprotein overexpression in mouse cells does not correlate with resistance to N-benzyladriamycin-14-valerate (AD 198).
    Lothstein L, Koseki Y, Sweatman TW.
    Anticancer Drugs; 1994 Dec 15; 5(6):623-33. PubMed ID: 7888699
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
    Cole SP, Chanda ER, Dicke FP, Gerlach JH, Mirski SE.
    Cancer Res; 1991 Jul 01; 51(13):3345-52. PubMed ID: 1675932
    [Abstract] [Full Text] [Related]

  • 9. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
    Abbaszadegan MR, Cress AE, Futscher BW, Bellamy WT, Dalton WS.
    Cancer Res; 1996 Dec 01; 56(23):5435-42. PubMed ID: 8968098
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin.
    Evans CH, Baker PD.
    Cancer Res; 1992 Nov 01; 52(21):5893-9. PubMed ID: 1356622
    [Abstract] [Full Text] [Related]

  • 12. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.
    Ganapathi R, Kuo T, Teeter L, Grabowski D, Ford J.
    Mol Pharmacol; 1991 Jan 01; 39(1):1-8. PubMed ID: 1670962
    [Abstract] [Full Text] [Related]

  • 13. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
    Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, Santi S, Ferracini R, Maraldi NM.
    Eur J Cell Biol; 1995 Nov 01; 68(3):226-39. PubMed ID: 8603675
    [Abstract] [Full Text] [Related]

  • 14. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells.
    Keizer HG, Schuurhuis GJ, Broxterman HJ, Lankelma J, Schoonen WG, van Rijn J, Pinedo HM, Joenje H.
    Cancer Res; 1989 Jun 01; 49(11):2988-93. PubMed ID: 2566376
    [Abstract] [Full Text] [Related]

  • 15. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R, Grabowski D, Ford J, Heiss C, Kerrigan D, Pommier Y.
    Cancer Commun; 1989 Jun 01; 1(4):217-24. PubMed ID: 2576973
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
    Slovak ML, Hoeltge GA, Dalton WS, Trent JM.
    Cancer Res; 1988 May 15; 48(10):2793-7. PubMed ID: 2896069
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
    Lothstein L, Savranskaya L, Sweatman TW.
    Leuk Res; 2007 Aug 15; 31(8):1085-95. PubMed ID: 17187856
    [Abstract] [Full Text] [Related]

  • 20. Reversal of multidrug resistance by verapamil and modulation by alpha 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines.
    Chatterjee M, Robson CN, Harris AL.
    Cancer Res; 1990 May 01; 50(9):2818-22. PubMed ID: 1970277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.